Eight major RCTs of GLP-1RAs have investigated the cardiovascular outcomes, including the ELIXA trial of lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT trial of subcutaneous semaglutide (199)
Clin Cancer Res 9(1):228234 Brady M, Spiker AM (2018) Merkel cell carcinoma of the skin Bronner MP, Culin C, Reed JC, Furth EE (1995) The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model
If you're receiving your first shipment at home, our team will provide thorough guidanceeither in person or over the phoneto ensure you're comfortable and confident with self-administering your medication
10.1038/s41568-020-0273-y 142 LeoneR
R&D Clinical Trials and Regulatory Approvals Patient Support and Services Chirag and Chintu Patel, Co-Chief Executive Officers of Amneal Pharmaceuticals, commented on collaboration with Metsera that the company could extend its pipeline to a new portfolio of injectable and oral weight loss GLP-1 therapies